Annual Report 2024
Rare Cancer Center
(Hospital) Akira Kawai, Yoko Katoh, Yoshitaka Narita, Shigenobu Suzuki, Seiichi Yoshimoto, Naoya Yamazaki, Koji Izutsu, Noboru Yamamoto, Yoshitaka Honma, Tatsunori Shimoi, Kazuki Sudo, Aiko Maejima, Yasushi Goto, Hidekazu Hirano, Chigusa Morizane, Susumu Hijioka, Motokiyo Komiyama, Eisuke Kobayashi, Shintaro Iwata, Kenjiro Namikawa, Wataru Munakata, Ayumu Arakawa, Miyuki Sone, Akihiko Yoshida, Takuro Sakurai, Taro Shibata, etc.
(Hospital East) Naoto Gotohda, Yoichi Naito, Ako Hosono, Junya Ueno
Introduction
The Rare Cancer Center, established in June 2014, comprises expert health care providers from various units and provides state-of-the-art, optimal medical care for rare cancers. It also promotes cutting-edge research and treatment development, clarifies and addresses issues in medical care for rare cancers through medical care and research. The Rare Cancer Center plays an important role in measures against rare cancers, not only in the National Cancer Center but also all over Japan. The National Institute for Rare Cancers in Japan was assigned to the National Cancer Center in April 2018. Rare cancers are defined as those with an incidence < 6/100,000/year. Although each subtype of rare cancer is in itself rare, it accounts for up to 15% of all newly diagnosed cancer cases when the number of each subtype of rare cancer is combined. Information on rare cancers has been lacking to date, which makes it difficult for clinicians to diagnose rare cancer correctly and to treat patients appropriately. Another problem is the lack of experienced experts in the field of rare cancers.
The Team and What We Do
The Rare Cancer Center has been playing a central role in the management of rare cancers in the National Cancer Center (NCC).
The mission statements of the Rare Cancer Center are as follows:
1. Establishing a vital network for diagnosis and treatment for rare cancers.
2. Investigating the problems associated with rare cancers, addressing the issues and making proposals as medical professionals for rare cancers.
The Rare Cancer Center provides specialized and high-quality medical care to patients with rare cancers and promotes research through a multidisciplinary approach. Monthly regular web-conferences are held between the Tsukiji and Kashiwa campuses to discuss issues in the treatment of rare cancers.
Research Activities
To deliver information on rare cancers, a website for patients with rare cancers and their families (https://www.ncc.go.jp/jp/rcc/index.html) has been launched, and 500 new pieces of content were added in 2024. In addition, information is disseminated via Facebook to provide it in a timely manner, and 505 posts were made in 2024. Rare Cancer Leaflets for 54 subtypes of rare cancers were created and distributed.
Since 2017, "Rare Cancer Meet the Expert," a seminar on rare cancers, has been held for patients and their families. In September 2022, it was relaunched as an event entitled "Online Rare Cancer Meet the Expert," and in 2024, 17 seminars were held with 3,698 viewers. The cumulative number of views of the 325 videos was 1,495,114. A new project, "Rare Cancer Consultation Q&A," was held three times in 2024. This is a lecture in which the lecturer, a doctor involved in rare cancer treatment and research, answers questions from patients regarding diseases such as diagnosis and treatment in a general manner. We also held five seminars on rare cancer treatment in collaboration with nine patient advocacy groups.
We promoted Cancer Awareness Month covering eight rare cancers, including mesothelioma and lymphoma, in collaboration with the patient advocacy group.
For the project "Research on rare cancers to generate and utilize evidence in patient care in rare cancers" funded by the Cancer Research and Development Fund, members of the Rare Cancer Center took a leading role in conducting research on understanding the status of medical treatment for rare cancers, information dissemination, and education. In addition, in the project "Research on developing a nationwide for providing cancer information and consultation support for rare cancers" funded by the Ministry of Health, Labour and Welfare Grants-in-aid for Scientific Research program, the Rare Cancer Center worked toward maintaining a network of hospitals treating rare cancers that was consistent with the situation in each region of Japan.
In 2022, the Rare Cancer Grant Program was established based on several donations to the Rare Cancer Center from people who supported its initiatives and actions. We called for applications for research funding and subsequently supported 19 researchers conducting leading-edge research at the Rare Cancer Center. On November 30, 2024, the Commemorative Symposium for the National Cancer Center Grant-in-Aid for Rare Cancer Research (Figure 1) (https://www.ncc.go.jp/jp/rcc/rcgrant/0158/index.html) was held. In collaboration and cooperation with patient groups and support organizations, this symposium was held under the slogan "Building a Bridge to the Future: Research, Community, Our Perspectives and Passions." Researchers and patient group representatives paired up to present research results, interact and exchange opinions with researchers and patients, present eight awards, and hold an exhibition titled "The Rare Cancer Center: A Decade of Progress" (Figure 2). It incorporated many new initiatives based on ideas from patient groups and support organizations. With 278 participants (patients, family members, researchers, healthcare professionals, etc.) (Figure 3) and a satisfaction rate of 98%, it received high praise and served as a crucial opportunity to deepen collaboration between researchers and the patient community. A digest video, a report, and an appendix titled "The Rare Cancer Center: A Decade of Progress" were produced as records.
Figure 2. The Rare Cancer Center: A Decade of Progress
Future Prospects
As the National Institute for Rare Cancers in Japan, our missions are to develop networks connecting patients and healthcare providers across the nation, to promote extraordinary patient care, scientific research, and education on rare cancers. Tuning into the issues faced by all rare cancer patients, we address them from a global perspective.
List of papers published in 2024
Journal
1. Morii T, Ogura K, Sato K, Kawai A. Infection of surgery for bone and soft tissue sarcoma with biological reconstruction: Data from the Japanese nationwide bone tumor registry. Journal of orthopaedic science, 30:390-396, 2025
2. Winer LK, Akumuo R, Fredette JD, Deng M, Hasler JS, Greco SH, von Mehren M, Bartholomew AJ, Blazer DG, Gabrielova L, Adamkova D, Bernard-Bedard E, Nessim C, Kollár A, Olariu R, Cencelj-Arnez R, Hompes D, Ford SJ, Cardona K, Sato K, Iwata S, Farma JM, Villano AM. Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi-institutional collaborative. Cancer, 131:e35468, 2025
3. Tsuchiya K, Akisue T, Ehara S, Kawai A, Kawano H, Hiraga H, Hosono A, Hutani H, Morii T, Morioka H, Nishida Y, Oda Y, Ogose A, Shimose S, Yamaguchi T, Yamamoto T, Yoshida M. Japanese orthopaedic association (JOA) clinical practice guideline on the management of primary malignant bone tumors - Secondary publication. Journal of orthopaedic science, 30:1-17, 2025
4. Muramatsu S, Ogura K, Morizane C, Satake T, Toda Y, Iwata S, Kobayashi E, Higashi T, Ikeuchi M, Kawai A. Statistics of Visceral Sarcoma in Japan: Report From the Population-Based National Cancer Registry (NCR) in Japan. Journal of surgical oncology, 131:274-284, 2025
5. Fukuda A, Ogata D, Oshima Y, Nakano E, Namikawa K, Komatsu M, Nakamura A, Sugiura K, Yamazaki N. Grade 3 acute kidney injury caused anti-glomerular basement membrane nephritis during immune checkpoint inhibitor treatment for melanoma. The Journal of dermatology, 52:e168-e169, 2025
6. Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology, 86:365-372, 2025
7. Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Li ZC, Bae S, D'Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Koseła-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, Bovee JVMG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Gronchi A, Stacchiotti S. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease. The American journal of surgical pathology, 49:27-34, 2025
8. Kashihara T, Nakamura S, Yamazaki N, Takahashi A, Namikawa K, Ogata D, Nakano E, Okuma K, Kaneda T, Mori T, Ito K, Itami J, Shimada K, Nakagama H, Igaki H. Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial. Radiotherapy and oncology, 202:110607, 2025
9. Masunaga T, Tsukamoto S, Honoki K, Fujii H, Tanaka Y, Ishida Y, Tanaka Y, Mavrogenis A, Errani C, Kawai A. Wide surgical margins may be necessary to reduce recurrence and mortality in patients with localized periosteal chondrosarcoma: retrospective analysis of twenty three patients and literature meta-analysis. International orthopaedics, 49:279-288, 2025
10. Sekita T, Asano N, Kubo T, Totsuka H, Mitani S, Hattori N, Yoshida A, Kobayashi E, Komiyama M, Ushijima T, Nakayama R, Nakamura M, Kawai A, Ichikawa H. Early separation and parallel clonal selection of dedifferentiated and well-differentiated components in dedifferentiated liposarcoma. Neoplasia (New York, N.Y.), 59:101074, 2025
11. Wada S, Ishii T, Ogata D, Nakano E, Namikawa K, Yamazaki N, Higashi T. Clinical Features and Prognosis of Malignant Cutaneous Adnexal Tumors: A Retrospective Study Using a Japanese Database. Journal of surgical oncology, 131:1157-1164, 2025
12. Murase Y, Esaki M, Mizui T, Takamoto T, Nara S, Ban D, Hiraoka N, Shimada K. Optimal lymph node dissection area for pancreatic neuroendocrine neoplasms by tumor location, size, and grade. Surgery, 180:109029, 2025
13. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Satake T, Morizane C, Yamazaki N, Kawai A. Comprehensive epidemiology of melanoma at all sites: insights from Japan's National Cancer Registry, 2016-2017. International journal of clinical oncology, 30:194-198, 2025
14. Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay L, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma. Future oncology (London, England), 21:523-531, 2025
15. Fujii E, Kato MK, Ono H, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H. TP53 Mutations and PD-L1 Amplification in Vulvar Adenocarcinoma of the Intestinal Type: Insights From Whole Exome Sequencing of 2 Cases. International journal of gynecological pathology, 44:358-363, 2025
16. Ishikawa M. Rare malignant ovarian tumors: a review. Japanese journal of clinical oncology, 55:205-209, 2025
17. Jeys LM, Morris GV, Kurisunkal VJ, Botello E, Boyle RA, Ebeid W, Houdek MT, Puri A, Ruggieri P, Brennan B, Laitinen MK, Abad Repiso S, Abdelbary H, Abiad Mejia A, Abood AA, Abril Martin JC, Abudu A, Abu Elhamd A, Acosta M, Ae K, Agarwal M, Ajit Singh V, Akiyama T, Alshaygy I, Albergo JI, Alexander J, Alfaro PA, Alpan B, Amaya-Valero J, Anderson M, Andreou D, Annabell L, Anthony C, Aoude A, Arteagoitia-Colino I, Asavamongkolkul A, Aston W, Asua Mentxaka L, Azzopardi C, Baad-Hansen T, Badr IT, Baixauli-Garcia F, Baker G, Balach T, Baldi GG, Barry J, Basile G, Bastoni S, Basuki M, Bauer H, Bayliss L, Becker RG, Bedi A, Benevenia J, Bengoa F, Bergh P, Bergovec M, Bernthal N, Binitie O, Boddie D, Boffano M, Bonilla Huertas P, Borgognoni AB, Botchu R, Bramer J, Brar R, Branford-White H, Broekhuis D, Broida SE, Budny T, Burke ZD, Cabrolier J, Calvo-Haro JA, Calvo Tapies JR, Cardoso R, Carey Smith R, Carvallo PI, Casales Fresenga N, Casanova JM, Ceballos O, Cebrian Parra JL, Chacon Cartaya S, Chan CM, Cho YJ, Choong P, Chung YG, Ciechanowicz D, Clara-Altamirano MA, Clever D, Colina SM, Consuegra L, Couch C, Cribb G, Cuervo C, Cusick LA, Dadia S, Dagher T, Dammerer D, Davies M, Davies N, de la Rosa Martino LP, de Santos de la Fuente FJ, de Vaal M, Deckers C, Delgado Obando J, Deo S, Deventer N, Di Bella C, Domson G, Donati DM, Dorleijn DM, Du Toit J, Dunne D, Duran Ciarrochi R, Ekman E, El Ghoneimy AM, Endo M, Eralp L, Etaiwi M, Evans S, Evrard R, Eward W, Farese A, Ferguson PC, Ferreira Cardoso PF, Fiorenza F, Flint M, Flores H, Freitas J, Fuchs B, Fujiwara T, Funovics PT, Galli Serra M, Gamie Z, Garces-Zarzalejo C, Gazendam A, Gebert C, Gerbers JG, Gerrand C, Abou-Nouar G, Ghert M, Ghosh KM, Gibbons M, Gomez-Mier LC, Gomez-Vallejo J, Gomez-Mascard A, Gonzalez MR, Gonzalez-Lizan F, Gosheger G, Goudie S, Goulding K, Goumenos SD, Griffin A, Gulia A, Gupta S, Gupta A, Guzman M, Haitham M, Hardes J, Hardoy F, Hasan Y, et al. (複数名のため一部抜粋して記載。詳細は掲載先をご参照ください). Identifying consensus and areas for future research in chondrosarcoma : a report from the Birmingham Orthopaedic Oncology Meeting. The bone & joint journal, 107-B:246-252, 2025
18. Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kobayashi E, Higashi T, Kawai A. Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Japanese journal of clinical oncology, 55:490-497, 2025
19. Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. Update for: New developments in systemic therapy for advanced biliary tract cancer. Japanese journal of clinical oncology, 55:210-218, 2025
20. Toda Y, Ogura K, Morizane C, Satake T, Iwata S, Kobayashi E, Takemori T, Kondo H, Muramatsu S, Higashi T, Kawai A. Prognostic factors and management of elderly sarcoma in Japan: the population-based National Cancer Registry (NCR) in Japan. International journal of clinical oncology, 30:1018-1032, 2025
21. Winer LK, Fredette JD, Hasler J, Akumuo R, Greco SH, von Mehren M, Bartholomew AJ, Blazer DG, Gabrielova L, Adamkova D, Bernard-Bedard E, Nessim C, Kollár A, Olariu R, Cencelj-Arnez R, Hompes D, Ford SJ, Cardona K, Sato K, Iwata S, Farma JM, Villano AM. Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans: An International, Multi-Institutional Study. Annals of surgical oncology, 32:3752-3762, 2025
22. Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kondo H, Kobayashi E, Higashi T, Kawai A. Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019. Scientific reports, 15:9960, 2025
23. Nishino S, Mori T, Umezu H, Eguchi K, Hirai T, Yamada R, Ohshima S, Yatabe Y, Yoshimoto S, Kawai A, Motoi T, Yoshida A. Nosologic Reappraisal of the Recently Proposed Calcified Chondroid Mesenchymal Neoplasm Concept in a Series of 20 Cases. Modern pathology, 38:100762, 2025
24. Iwata S, Noguchi R, Osaki J, Adachi Y, Shiota Y, Ogura K, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma. Human cell, 38:81, 2025
25. Furukawa N, Hasegawa N, Kubota D, Nakamura Y, Tanaka H, Iwata S, Kawai A, Saito T, Takagi T, Kohsaka S, Ishijima M. Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumours. BMC cancer, 25:587, 2025
26. Tsuchiya R, Ogura K, Ohtori S, Kawai A. Statistics of Primary Malignant Spine Tumors in Japan: A Retrospective Study Using the Bone and Soft Tissue Tumor Registry in Japan. Spine, 2025
27. Morii T, Ogura K, Sato K, Kawai A. Incidence and risk of surgical site infection/periprosthetic joint infection in tumor endoprosthesis-data from the nationwide bone tumor registry in Japan. Journal of orthopaedic science, 29:1112-1118, 2024
28. Morii T, Sato K, Ogura K, Kawai A. Incidence and risk of infection in malignant soft tissue tumor resection: Data from the nationwide soft tissue tumor registry. Journal of orthopaedic science, 29:1300-1305, 2024
29. Fukushima T, Okita Y, Watanabe N, Yokota S, Nakano J, Kawai A. Evaluation of clinical factors associated with early postoperative physical function and lower extremity functional impairment in patients with soft tissue sarcoma. Disability and rehabilitation, 46:3426-3431, 2024
30. Kojima N, Kubo T, Mori T, Satomi K, Matsushita Y, Iwata S, Yatabe Y, Ichimura K, Kawai A, Ichikawa H, Yoshida A. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study. Virchows Archiv, 484:71-81, 2024
31. Fukushima T, Watanabe N, Okita Y, Yokota S, Kurita D, Ishiyama K, Oguma J, Kawai A, Daiko H. Preoperative physical activity is associated with prognosis in patients with esophageal cancer undergoing thoracoscopic-laparoscopic esophagectomy after neoadjuvant chemotherapy. General thoracic and cardiovascular surgery, 72:134-143, 2024
32. Mori T, Kobayashi E, Sato Y, Takenaka S, Endo M, Nakamura T, Morii T, Yoshida Y, Ueda T, Kawano H, Kawai A. What Are the Complication Rates and Factors Associated With Total Femur Replacement After Tumor Resection? Findings From the Japanese Musculoskeletal Oncology Group. Clinical orthopaedics and related research, 482:702-712, 2024
33. Odate T, Satomi K, Kubo T, Matsushita Y, Ueno T, Kurose A, Shomori K, Nakai T, Watanabe R, Segawa K, Ohshika S, Miyake N, Kudo S, Shimoi T, Kobayashi E, Komiyama M, Yoshimoto S, Nakatani F, Kawai A, Yatabe Y, Kohsaka S, Ichimura K, Ichikawa H, Yoshida A. Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Modern pathology, 37:100359, 2024
34. Yoshimatsu Y, Noguchi R, Osaki J, Sin Y, Tsuchiya R, Ono T, Akiyama T, Adachi Y, Tanzawa Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma. Human cell, 37:337-344, 2024
35. Watanabe T, Honma Y, Yonemori K, Sunami K, Yoshimoto S, Mori T. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor. Head & neck, 46:E26-E31, 2024
36. Masunaga T, Tsukamoto S, Nitta Y, Honoki K, Fujii H, Akahane M, Takeda M, Tanaka Y, Mavrogenis AF, Errani C, Kawai A. Is perioperative chemotherapy effective in patients with localized myxoid liposarcoma? Japanese journal of clinical oncology, 54:297-304, 2024
37. Kobayashi H, Okajima K, Zhang L, Hirai T, Ishibashi Y, Tsuda Y, Ikegami M, Kawai A, Tanaka S. Prognostic factors and treatment outcomes in patients with pleomorphic rhabdomyosarcoma: a population-based cohort study. Japanese journal of clinical oncology, 54:471-478, 2024
38. Wada S, Nakano E, Nakajima M, Kishikawa S, Yoshida A, Mori T, Osada A, Ogata D, Namikawa K, Yamazaki N. Congenital dermatofibrosarcoma protuberans on the scalp enlarging and shrinking repeatedly. The Journal of dermatology, 51:e196-e197, 2024
39. Shimizu J, Emori M, Murahashi Y, Kawai A, Teramoto A. Clinical outcomes in patients with adamantinoma: Report from the bone and soft tissue tumor registry in Japan. Journal of surgical oncology, 129:1000-1005, 2024
40. Ono T, Noguchi R, Osaki J, Akiyama T, Adachi Y, Kojima N, Toda Y, Fukushima S, Yoshimatsu Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Human cell, 37:854-864, 2024
41. Rikitake R, Mizushima Y, Yoshimoto S, Higashi T, Satake T, Morizane C, Kawai A. Current status of head and neck sarcomas in Japan in 2016-2019: an analysis using the national cancer registry. International journal of clinical oncology, 29:564-570, 2024
42. Uhara H, Kiyohara Y, Isei T, Nagase K, Kambe A, Sato M, Tanaka Y, Yamazaki N. Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. The Journal of dermatology, 51:475-483, 2024
43. Aiba H, Kojima Y, Shimoi T, Sudo K, Yazaki S, Imai T, Yoshida A, Iwata S, Kobayashi E, Kawai A, Arakawa A, Ogawa C, Kimura H, Yonemori K. Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan. Cancer medicine, 13:e7060, 2024
44. Adachi Y, Noguchi R, Yoshimatsu Y, Sin Y, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Ishihara S, Ogura K, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1. Human cell, 37:874-885, 2024
45. Osaki J, Noguchi R, Yanagihara K, Ono T, Adachi Y, Iwata S, Toda Y, Sekita T, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma. Human cell, 37:865-873, 2024
46. Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO open, 9:102981, 2024
47. Hijioka S, Yamashige D, Esaki M, Honda G, Higuchi R, Masui T, Shimizu Y, Ohtsuka M, Kumamoto Y, Katanuma A, Gotohda N, Akita H, Unno M, Endo I, Yokoyama Y, Yamada S, Matsumoto I, Ohtsuka T, Hirano S, Yasuda H, Kawai M, Aoki T, Nakamura M, Hashimoto D, Rikiyama T, Horiguchi A, Fujii T, Mizuno S, Hanada K, Tani M, Hatori T, Ito T, Okuno M, Kagawa S, Tajima H, Ishii T, Sugimoto M, Onoe S, Takami H, Takada R, Miura T, Kurita Y, Kamei K, Mataki Y, Okazaki K, Takeyama Y, Yamaue H, Satoi S. Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies. Clinical gastroenterology and hepatology, 22:1416-1426.e5, 2024
48. Watanabe Y, Chen YW, Igaki H, Arakawa A, Tao K, Sugiyama M, Nakajima M, Shirakawa N, Yanagisawa S, Miyakita Y, Yoshida A, Isohashi K, Ono K, Narita Y, Ogawa C. Boron neutron capture therapy prolongs survival in a patient with a recurrent malignant peripheral nerve sheath tumor-A case report. Pediatric blood & cancer, 71:e31011, 2024
49. Imai T, Kojima Y, Shimoi T, Aiba H, Okuma HS, Saito A, Kita S, Yamamoto K, Maejima A, Nishikawa T, Sudo K, Noguchi E, Yoshida A, Matsui Y, Iwata S, Kobayashi E, Kawai A, Udagawa R, Fujiwara Y, Yonemori K. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. Anticancer research, 44:2125-2132, 2024
50. Kobayashi H, Okajima K, Zhang L, Hirai T, Ishibashi Y, Tsuda Y, Ikegami M, Kawai A, Tanaka S. Embryonal and alveolar rhabdomyosarcoma in adolescents/young adults, adults and older adults: a population-based cohort study. Japanese journal of clinical oncology, 54:903-910, 2024
51. Umino R, Nara S, Mizui T, Takamoto T, Ban D, Esaki M, Hiraoka N, Shimada K. Impact of Surgical Margin Status on Survival and Recurrence After Pancreaticoduodenectomy for Distal Cholangiocarcinoma: Is Microscopic Residual Tumor (R1) Associated with Higher Rates of Local Recurrence? Annals of surgical oncology, 31:4910-4921, 2024
52. Sugiyama M, Arakawa A, Iwata S, Tao K, Shirakawa N, Watanabe Y, Nakajima M, Yoshida A, Ishigaki K, Kawai A, Ogawa C. Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy. Pediatric blood & cancer, 71:e31036, 2024
53. Torasawa M, Yoshida T, Shiraishi K, Goto N, Ueno T, Ichikawa H, Yagishita S, Kohsaka S, Goto Y, Yatabe Y, Hamada A, Mano H, Ohe Y. Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report. JTO clinical and research reports, 5:100657, 2024
54. Nakano E, Takahashi A, Ogata D, Namikawa K, Yamazaki N. Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan. The Journal of dermatology, 51:1199-1207, 2024
55. Umino R, Nara S, Mizui T, Takamoto T, Ban D, Esaki M, Hiraoka N, Shimada K. ASO Author Reflections: Future Perspectives in Surgical Management of Distal Cholangiocarcinoma: Insights from Surgical Margin Status and Recurrence Patterns. Annals of surgical oncology, 31:4946-4947, 2024
56. Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European journal of cancer (Oxford, England : 1990), 204:114073, 2024
57. Kawai A, Yoshida A, Shimoi T, Kobayashi E, Yonemori K, Ogura K, Iwata S, Toshirou N. Histological diagnostic discrepancy and its clinical impact in bone and soft tissue tumors referred to a sarcoma center. Cancer science, 115:2831-2838, 2024
58. Muto Y, Fujimura T, Takahashi A, Namikawa K, Ogata D, Nakano E, Jinnai S, Hashimoto A, Kambayashi Y, Asano Y, Yamazaki N. Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A multicenter study of 116 Japanese patients. The Journal of dermatology, 51:1225-1232, 2024
59. Fiore M, Sarre-Lazcano C, Smith M, Khan M, Raut CP, Honoré C, Sargos P, Cananzi F, Grignani G, Iwata S, Gronchi A. Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). The British journal of surgery, 111:znae128, 2024
60. Oguro S, Chen YN, Yamane T, Mohri M, Suzuki S. Selective ophthalmic arterial injection using a balloon catheter for retinoblastoma: a seven-year clinical evaluation. Japanese journal of ophthalmology, 68:346-354, 2024
61. Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kobayashi E, Arakawa A, Ogawa C, Kato Y, Higashi T, Kawai A. Statistics of bone sarcoma in Japan: report from the population-based cancer registry in Japan. International journal of clinical oncology, 29:1209-1219, 2024
62. Tanese K, Ogata D. The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma. Experimental dermatology, 33:e15122, 2024
63. Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, Utsumi Y, Nakatogawa T, Takano R, Fujii K, Koroki Y, Aoyama J, Ouchi S, Ogawa T, McCarthy S, Brookman-May SD, Mundle S, Li J, Thaper D, Nagao T, Tada Y. Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. Clinical cancer research, 30:3416-3427, 2024
64. Kawasaki Y, Hijioka S, Nagashio Y, Ohba A, Maruki Y, Takeshita K, Takasaki T, Agarie D, Hagiwara Y, Hara H, Okamoto K, Yamashige D, Kondo S, Morizane C, Ueno H, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Saito Y, Hiraoka N, Okusaka T. Diagnostic performance of EUS-guided tissue acquisition for solid pancreatic lesions ≦10 mm. Endoscopic ultrasound, 13:115-122, 2024
65. Tanaka T, Goto Y, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas. Respiratory investigation, 62:766-772, 2024
66. Nishino S, Kojima N, Sugino H, Mori T, Yatabe Y, Yoshida A. MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma. Virchows Archiv, 485:359-363, 2024
67. Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kondo H, Kobayashi E, Katoh Y, Higashi T, Kawai A. Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019. Japanese journal of clinical oncology, 54:1150-1157, 2024
68. Toda Y, Ogura K, Iwata S, Kobayashi E, Osaki S, Fukushima S, Mawatari M, Kawai A. The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone. International journal of clinical oncology, 29:1391-1397, 2024
69. Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer discovery, 14:2243-2261, 2024
70. Itoyama M, Ohara A, Yokoyama K, Yamamoto S, Kato K, Tada Y, Sugitani A, Sugino H, Yatabe Y, Kusumoto M, Nakamura K, Honma Y. An autopsy case of pulmonary tumor thrombotic microangiopathy that developed during chemotherapy for salivary duct carcinoma of the parotid gland. Auris, nasus, larynx, 51:829-833, 2024
71. Nishikawa T, Kakunaga S, Tamura K, Ando M, Ozaki T, Kawai A, Ueda T, Kawasaki M, Tomatsuri S, Okamura N, Kamikura M, Hamada A, Yoshida A, Hirakawa A, Shibata T, Nakamura K, Yonemori K. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer, 130:3836-3844, 2024
72. Tsuruta S, Ogata D, Namikawa K, Nakano E, Yamazaki N. A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options. Japanese journal of clinical oncology, 54:1135-1140, 2024
73. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology, 42:3207-3217, 2024
74. Hasei J, Ishida H, Katayama H, Maeda N, Nagano A, Ochi M, Okamura M, Iwata S, Ikuta K, Yoshida S, Fujiwara T, Nakata E, Nakahara R, Kunisada T, Ozaki T. Utilizing the Metaverse to Provide Innovative Psychosocial Support for Pediatric, Adolescent, and Young Adult Patients with Rare Cancer. Cancers, 16:2617, 2024
75. Arikawa M, Akazawa S, Kageyama D, Kawai A, Ohe Y, Sakisaka M, Miyamoto S. Nonreversed great saphenous vein grafts for vascular reconstruction after resection of lower-limb sarcoma. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 97:65-70, 2024
76. Osaki J, Noguchi R, Ono T, Adachi Y, Iwata S, Toda Y, Funada T, Iwata S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS6-C1: a novel patient-derived cell line of synovial sarcoma. Human cell, 37:1734-1741, 2024
77. Hosoi H, Miyachi M, Teramukai S, Sakabayashi S, Tsuchiya K, Kuwahara Y, Onodera R, Matsuyama K, Yokota I, Hojo H, Okita H, Hata JI, Hamasaki M, Tsuneyoshi M, Oda Y, Nakazawa A, Kato M, Takimoto T, Horibe K, Hara JI, Suita S, Hanada R, Masaki H, Nozaki M, Ikeda H, Kishimoto S, Kaneko M, Kawai A, Morikawa Y. Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma. International journal of clinical oncology, 29:1746-1755, 2024
78. Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kondo H, Kobayashi E, Higashi T, Kawai A. Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan. Japanese journal of clinical oncology, 54:1281-1287, 2024
79. Adachi Y, Noguchi R, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Tetsuya S, Iwata S, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1. Human cell, 37:1742-1750, 2024
80. Giani C, Denu RA, Ljevar S, Gronchi A, Napolitano A, Rosenbaum E, Salawu A, Bajpai J, Connolly EA, Lee ATJ, Trent JC, Koseła-Paterczyk H, Chia-Chen Li Z, Ogura K, Palmerini E, Baldi GG, Brunello A, Campos F, Cicala CM, Maki RG, Wagner AJ, Andelkovic V, Loong HH, Wong DD, Jones RL, Tap WD, Taverna SM, Lazar AJ, Demicco EG, Hong A, Bovee JVMG, Dei Tos AP, Fletcher CDM, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Stacchiotti S. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO open, 9:103689, 2024
81. Uotani K, Fujiwara T, Ueda K, Yoshida A, Iwata S, Morita T, Kiyono M, Kunisada T, Takeda K, Hasei J, Yoshioka Y, Ochiya T, Ozaki T. Identification of ENO-1 positive extracellular vesicles as a circulating biomarker for monitoring of Ewing sarcoma. Cancer science, 115:3660-3671, 2024
82. Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M. 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). Journal of hepato-biliary-pancreatic sciences, 31:886-896, 2024
83. Ogawa A, Yoshida H, Kawano S, Kikkawa N, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M. Ovarian Mesonephric-like Adenocarcinoma: Its Prevalence in a Japanese High-Volume Cancer Center and a Literature Review on Therapeutic Targets. Current oncology (Toronto, Ont.), 31:5107-5120, 2024
84. Ueno M, Morizane C, Ikeda M, Ozaka M, Nagashima F, Kataoka T, Mizusawa J, Ohba A, Kobayashi S, Imaoka H, Kasuga A, Okano N, Nagasaka Y, Sasaki M, Furuse J, Okusaka T. Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE). ESMO open, 9:103919, 2024
85. Sekita T, Asano N, Kobayashi H, Yonemoto T, Kobayashi E, Ishii T, Kawai A, Nakayama R. Long-term functional outcome of limb-sparing surgery for paediatric bone sarcoma around the knee. Bone & joint open, 5:868-878, 2024
86. Noguchi R, Osaki J, Ono T, Adachi Y, Iwata S, Yoshimatsu Y, Sasaki K, Kawai A, Kondo T. Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning. In vitro cellular & developmental biology. Animal, 60:1200-1214, 2024
87. Fujii H, Hirano H, Shiraishi K, Shoji H, Hirose T, Okita N, Takashima A, Koyama T, Kato K. Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database. JCO precision oncology, 8:e2400284, 2024
88. Nakamura T, Ogura K, Hayakawa K, Ikuta K, Nezu Y, Miwa S, Yoshida S, Nakai S, Kinoshita H, Kawabata Y, Hamada S, Nabeshima A, Outani H, Kobayashi H, Hara H, Tsugita M, Koyanagi H, Setsu N, Maekawa A, Daisaku A, Mori T, Oike N, Kubota Y, Tanaka T, Noguchi T, Tajima T, Tanaka K, Ozaki T. Real-world Referral Pattern of Unplanned Excision in Patients With Soft-tissue Sarcoma: A Multicenter Study Conducted by the Bone and Soft-tissue Tumor Study Group of the Japan Clinical Oncology Group. In vivo (Athens, Greece), 38:2712-2717, 2024
89. Masunaga T, Tsukamoto S, Honoki K, Fujii H, Kido A, Akahane M, Tanaka Y, Mavrogenis AF, Errani C, Kawai A. Prognostic factors for mesenchymal chondrosarcoma. SICOT-J, 10:46, 2024
90. Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T. Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors. BJC reports, 2:54, 2024
91. Tsuchiya R, Iwata S, Fukushima S, Osaki S, Ogura K, Kobayashi E, Ohtori S, Kawai A. Developmental Patterns and Risk Factors of Scoliosis After Hemipelvectomy for the Pelvic Bone Tumor. Diagnostics (Basel, Switzerland), 14:2392, 2024
92. Sato C, Sugiyama M, Mori T, Nishino S, Tao K, Ogawa C, Yoshida A. Pediatric Mesenchymal Tumor With MN1::TAF3 Fusion. Genes, chromosomes & cancer, 63:e70009, 2024
93. Suehara Y, Kitada R, Kamio S, Ogura K, Iwata S, Kobayashi E, Kawai A, Khosaka S. Analysis of cancer multigene panel testing for osteosarcoma in pediatric and adults using the center for cancer genomics and advanced therapeutics database in Japan. Journal of orthopaedic science, S0949-2658(24)00209-4, 2024
94. Iwata S, Ono T, Noguchi R, Osaki J, Adachi Y, Shiota Y, Iwata S, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-GCTB14-C1 and NCC-GCTB15-C1: two novel patient-derived cell lines of giant cell tumor of bone. Human cell, 38:20, 2024
95. Tateishi A, Okuma Y, Goto Y, Arakaki M, Igawa YS, Torasawa M, Shinno Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice. Anticancer research, 44:5501-5513, 2024
96. Noguchi R, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y, Yanagihara K, Nishino S, Funada T, Ogura K, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1. Human cell, 38:28, 2024
97. Adachi Y, Noguchi R, Osaki J, Ono T, Akiyama T, Kondo H, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone. Human cell, 38:29, 2024
98. Yoshino J, Nara S, Yokoyama M, Ban D, Mizui T, Miyata A, Esaki M. Prognostic impact of lymph node dissection in intrahepatic cholangiocarcinoma: a propensity score analysis. Langenbeck's archives of surgery, 410:3, 2024
99. Umino R, Nara S, Mizui T, Takamoto T, Ban D, Esaki M, Hiraoka N, Shimada K. ASO Visual Abstract: Impact of Surgical Margin Status on Survival and Recurrence After Pancreaticoduodenectomy for Distal Cholangiocarcinoma: Is Microscopic Residual Tumor (R1) Associated with Higher Rates of Local Recurrence? Annals of surgical oncology, 31:8358-8359, 2024